Subsequent events

Subsequent events

On 12 March 2015, Janssen Pharmaceutica NV and Galapagos NV terminated their research alliance and option agreements to develop and commercialize compounds for the treatment of inflammation initially focusing on RA. All rights to the candidate drugs developed under these agreements are returned to Galapagos.